Table S11 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

dataset

posted on 2025-05-02, 07:26 authored by Miya B. Hugaboom, Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler, Valisha Shah, Jacob P. Zaemes, Nourhan El Ahmar, Sayed Matar, Varunika Savla, Toni K. Choueiri, Thomas Denize, Destiny J. West, David F. McDermott, Elizabeth R. Plimack, Jeffrey A. Sosman, Naomi B. Haas, Mark N. Stein, Robert Alter, Mehmet A. Bilen, Michael E. Hurwitz, Hans Hammers, Sabina Signoretti, Michael B. Atkins, Catherine J. Wu, David A. Braun

Signatures used for comparison of tumor, macrophage, and t cells from sarcomatoid and non-sarcomatoid tumors, related to Figures 4 and 5.

Funding

Bristol Myers Squibb Foundation (BMSF)

U.S. Department of Defense (DOD)

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

History

ARTICLE ABSTRACT

We describe a paradigm wherein combined high TLS and low tissue-resident exhausted CD8+ T cells are required for optimal response to PD-1 blockade in RCC. This analysis identifies key determinants of response to PD-1 blockade in advanced RCC and suggests avenues for future immune modulation through rational combination therapy strategies.